New Ray Medicine International Holding Limited (HKG:6108)

Revenue by Segment

Financials in millions HKD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Provision of Marketing and Promotion Services of Drugs	2.44M	5.24M	7.30M	6.02M	5.76M
Provision of Marketing and Promotion Services of Drugs Growth	-53.41%	-28.28%	21.36%	4.48%	27.41%
Distribution and Trading of Pharmaceutical Products	127.93M	88.71M	42.85M	83.75M	329.62M
Distribution and Trading of Pharmaceutical Products Growth	44.22%	107.01%	-48.84%	-74.59%	156.13%
Total	130.37M	93.95M	50.15M	89.77M	335.38M
Total Growth	38.78%	87.31%	-44.13%	-73.23%	151.76%

Revenue by Geography

Financials in millions HKD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
People's Republic of China (PRC)	130.37M	93.95M	50.15M	89.77M	335.38M
People's Republic of China (PRC) Growth	38.78%	87.31%	-44.13%	-73.23%	151.76%
Total	130.37M	93.95M	50.15M	89.77M	335.38M
Total Growth	38.78%	87.31%	-44.13%	-73.23%	151.76%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 21, 2026

Data Sources Report a data error